Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTA2-1 peptide-loaded PD-L-silenced donor dendritic cell vaccination with donor lymphocyte infusion after allogeneic stem cell transplantation
NL-OMON43853Phase 2Withdrawn
- Sponsor
- Vrije University Medical Center
- Start
- Oct 2015
- Modality
- Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UTA2-1 peptide-loaded PD-L-silenced donor dendritic cell vaccine and donor lymphocytes in multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by Vrije University Medical Center. Primary endpoints: Toxicity and feasibility and Immune status and antigen-specific immune response. Planned start Oct 2015; status: withdrawn.
02
Drugs
UTA2-1 peptide-loaded PD-L-silenced donor dendritic cell vaccinedonor lymphocytes
03
Conditions
multiple myeloma (MM)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)B-cell hematologic malignancies
Beyond the preview
Go deeper on NL-OMON43853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43853.